



Extracellular Matrix (ECM) Proteins in Chronic Diabetic Nephropathy: A Comprehensive Review.

Dr Anamika Singh Rathore¹, Dr Sherya Nighoskar²

¹Research Scholar, Malwanchal University, Indore

²Research Supervisor, Malwanchal University, Indore

Introduction

Diabetic nephropathy (DN) is one of the most severe complications of diabetes mellitus, affecting a significant proportion of diabetic patients. It is characterized by a progressive decline in kidney function, often leading to end-stage renal disease (ESRD). The pathogenesis of DN is multifactorial, involving complex interactions between hemodynamic and metabolic factors. A critical aspect of DN's progression is the alteration in the extracellular matrix (ECM) proteins within the kidney. These alterations contribute to glomerulosclerosis and tubulointerstitial fibrosis, hallmarks of chronic DN. This article delves into the role of ECM proteins in DN, exploring their functions, regulation, and potential as therapeutic targets.

The Extracellular Matrix: An Overview

The ECM is a dynamic network of proteins and glycoproteins that provide structural support to tissues and play a pivotal role in cellular signaling. In the kidney, the ECM components include collagen, laminin, fibronectin, and proteoglycans, which form the basement membrane and interstitial matrix. The balance between ECM synthesis and degradation is crucial for maintaining tissue homeostasis. In chronic DN, this balance is disrupted, leading to excessive ECM accumulation and fibrosis.

ECM Proteins and Their Roles in the Kidney

- Collagen:** Collagens are the most abundant ECM proteins, providing tensile strength and structural integrity. Type IV collagen is a major component of the glomerular basement membrane (GBM), while types I and III are predominant in the interstitial matrix. In DN, there is an upregulation of collagen types I, III, and IV, contributing to thickening of the GBM and interstitial fibrosis.
- Fibronectin:** Fibronectin is a glycoprotein that facilitates cell adhesion, growth, and wound healing. In DN, increased fibronectin deposition is observed, particularly in the GBM and mesangium, promoting glomerulosclerosis.
- Laminin:** Laminins are essential for basement membrane structure and function. Laminin isoforms in the GBM are altered in DN, leading to changes in cell-matrix interactions that promote pathological remodeling.
- Proteoglycans:** These are ECM components that consist of a core protein with glycosaminoglycan (GAG) chains. They regulate filtration barrier properties and sequester growth factors. In DN, changes in proteoglycan composition and distribution contribute to GBM thickening and altered filtration.

Pathophysiological Mechanisms of ECM Alterations in DN

The accumulation of ECM proteins in DN is driven by several interconnected mechanisms:

- Hyperglycemia:** Chronic high blood glucose levels stimulate the production of ECM proteins and reduce their degradation. Advanced glycation end products (AGEs) formed under hyperglycemic conditions further contribute to ECM protein cross-linking and accumulation.
- Transforming Growth Factor-beta (TGF- β):** TGF- β is a potent fibrogenic cytokine that promotes ECM protein synthesis and inhibits their degradation. In DN, TGF- β signaling is upregulated, leading to increased production of collagen, fibronectin, and other ECM components.
- Renin-Angiotensin-Aldosterone System (RAAS):** The RAAS is activated in DN, leading to increased angiotensin II levels, which stimulate ECM protein production and inhibit their degradation. Angiotensin II also promotes TGF- β expression, creating a vicious cycle of ECM accumulation.

4. **Inflammation:** Chronic inflammation in DN involves infiltration of immune cells that release cytokines and growth factors, further stimulating ECM protein synthesis and deposition.

Clinical Implications of ECM Alterations in DN

The excessive accumulation of ECM proteins in the kidney leads to structural and functional alterations that contribute to DN progression:

1. **Glomerulosclerosis:** The thickening of the GBM and mesangial expansion due to ECM protein deposition results in glomerulosclerosis, impairing glomerular filtration and leading to proteinuria.
2. **Tubulointerstitial Fibrosis:** Increased ECM protein deposition in the tubulointerstitium causes fibrosis, disrupting tubular function and leading to a decline in renal function.
3. **Microalbuminuria and Proteinuria:** The initial sign of DN is often microalbuminuria, progressing to overt proteinuria as ECM accumulation advances, reflecting significant kidney damage.

Potential Therapeutic Targets

Given the critical role of ECM proteins in DN, targeting the pathways involved in their regulation offers potential therapeutic strategies:

1. **TGF- β Inhibitors:** Therapies aimed at inhibiting TGF- β signaling can reduce ECM protein synthesis and fibrosis. Agents such as monoclonal antibodies against TGF- β and small molecule inhibitors of TGF- β receptors are under investigation.
2. **AGE Inhibitors and Breakers:** Inhibiting the formation of AGEs or breaking existing AGE cross-links can mitigate ECM protein cross-linking and accumulation. Aminoguanidine and ALT-711 are examples of such agents.
3. **RAAS Blockade:** ACE inhibitors and angiotensin II receptor blockers (ARBs) are standard treatments in DN, reducing ECM protein synthesis by blocking RAAS activation.
4. **Anti-Inflammatory Agents:** Targeting inflammatory pathways with agents such as corticosteroids, mycophenolate mofetil, and pentoxifylline can reduce ECM protein production and fibrosis.
5. **Matrix Metalloproteinase (MMP) Modulators:** MMPs are enzymes that degrade ECM proteins. Modulating MMP activity can help restore the balance between ECM synthesis and degradation.

Conclusion

The role of ECM proteins in the progression of chronic diabetic nephropathy is multifaceted and pivotal. Understanding the mechanisms underlying ECM alterations provides insight into potential therapeutic targets to halt or reverse kidney damage in DN. Current research continues to explore novel strategies to modulate ECM dynamics, aiming to improve outcomes for patients with this debilitating condition. As our knowledge expands, the hope is that more effective treatments will emerge, offering better quality of life for those affected by diabetic nephropathy.

Future Directions

The ongoing research in the field of ECM and DN holds promise for new therapeutic approaches. Some of the future directions include:

1. **Gene Therapy:** Targeting specific genes involved in ECM protein synthesis and regulation through gene editing techniques like CRISPR/Cas9 could offer precise therapeutic interventions.
2. **Stem Cell Therapy:** Utilizing stem cells to regenerate damaged kidney tissue and modulate ECM protein deposition is an area of active investigation.
3. **Biomarkers:** Identifying specific biomarkers related to ECM protein alterations could enable early diagnosis and monitoring of DN progression and response to therapy.
4. **Combination Therapies:** Using a combination of therapies targeting different pathways involved in ECM regulation may offer synergistic effects and improve treatment efficacy.
5. **Precision Medicine:** Personalized treatment approaches based on individual patient profiles, including genetic, metabolic, and ECM protein alterations, could optimize therapeutic outcomes.

In conclusion, the study of ECM proteins in chronic diabetic nephropathy is crucial for understanding the disease's pathogenesis and developing effective treatments. While significant progress has been made, ongoing research and innovative therapeutic strategies hold the potential to transform the management of DN, ultimately improving patient outcomes and quality of life.

REFERENCE

1. Cho N.H., Shaw J.E., Karuranga S., Huang Y., da Rocha Fernandes J.D., Ohlrogge A.W., Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res. Clin. Pract.* 2018;138:271–281. doi: 10.1016/j.diabres.2018.02.023. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
2. Gregg E.W. Complications of diabetes in elderly people. *BMJ.* 2002;325:916–917. doi: 10.1136/bmj.325.7370.916. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
3. Chow E.A., Foster H., Gonzalez V., McIver L. The Disparate Impact of Diabetes on Racial/Ethnic Minority Populations. *Clin. Diabetes.* 2012;30:130–133. doi: 10.2337/diaclin.30.3.130. [[CrossRef](#)] [[Google Scholar](#)]
4. Beckman J.A., Creager M.A. Vascular complications of diabetes. *Circ. Res.* 2016;118:1771–1785. doi: 10.1161/CIRCRESAHA.115.306884. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
5. Garcia M.J., McNamara P.M., Gordon T., Kannel W.B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. *Diabetes Care.* 1974;23:105–111. doi: 10.2337/diab.23.2.105. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
6. Biswas S., Thomas A.A., Chakrabarti S. LncRNAs: Proverbial Genomic “Junk” or Key Epigenetic Regulators During Cardiac Fibrosis in Diabetes? *Front. Cardiovasc. Med.* 2018;5:28. doi: 10.3389/fcvm.2018.00028. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature.* 2001;414:813–820. doi: 10.1038/414813a. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
8. Fioretto P., Mauer M. Histopathology of Diabetic Nephropathy. *Semin. Nephrol.* 2007;27:195–207. doi: 10.1016/j.semnephrol.2007.01.012. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
9. Roy S., Bae E., Amin S., Kim D. Extracellular matrix, gap junctions, and retinal vascular homeostasis in diabetic retinopathy. *Exp. Eye Res.* 2015;133:58–68. doi: 10.1016/j.exer.2014.08.011. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
10. Asbun J., Villarreal F.J. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. *J. Am. Coll. Cardiol.* 2006;47:693–700. doi: 10.1016/j.jacc.2005.09.050. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
11. Khan Z.A., Chakrabarti S. Chronic Diabetic Complications: Endothelial Cells at the Frontline. *Front. Cardiovasc. Drug Discov.* 2010;1:121–137. doi: 10.2174/97816080516011100101. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
12. Kumagai A.K. Glucose transport in brain and retina: Implications in the management and complications of diabetes. *Diabetes Metab. Res. Rev.* 1999;15:261–273. doi: 10.1002/(SICI)1520-7560(199907/08)15:4<261::AID-DMRR43>3.0.CO;2-Z. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
13. Feng B., Ruiz M.A., Chakrabarti S. Oxidative-stress-induced epigenetic changes in chronic diabetic complications. *Can. J. Physiol. Pharmacol.* 2013;91:213–220. doi: 10.1139/cjpp-2012-0251. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
14. Teti A. Regulation of cellular functions by extracellular matrix. *J. Am. Soc. Nephrol.* 1992;2(Suppl. 10):S83–S87. [[PubMed](#)] [[Google Scholar](#)]
15. Boudreau N.J., Jones P.L. Extracellular matrix and integrin signalling: The shape of things to come. *Biochem. J.* 1999;339:481–488. doi: 10.1042/bj3390481. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]